Duodenal “gut reset” offers a potential solution for post‑GLP‑1 weight maintenance

Clinical takeaway: For patients unwilling or unable to continue long‑term GLP‑1 therapy due to cost, tolerability, or preference, duodenal mucosal resurfacing may emerge as a future option to help maintain weight loss after medication discontinuation—pending longer follow‑up and broader clinical availability.

Weight regain after discontinuation of GLP‑1 receptor agonists is a growing clinical challenge, with an estimated 70% of patients regaining much of their lost weight within 18 months. New data presented at DDW 2026 suggest a potential procedural “off‑ramp” for patients who stop pharmacotherapy.

Researchers reported interim results from the REMAIN‑1 trial, the first blinded, randomized, sham‑controlled study evaluating duodenal mucosal resurfacing (DMR) after GLP‑1 discontinuation. The outpatient endoscopic procedure uses targeted thermal ablation to renew the duodenal mucosa, aiming to “reset” gut‑mediated metabolic signaling.

The midpoint cohort included 45 adults who had previously lost ≥15% of total body weight on tirzepatide—approximately 40 lb on average—before stopping the medication. Of these patients, 29 underwent DMR and 16 received a sham procedure. At 6 months post‑discontinuation, the sham group regained ~40% more weight than those treated with DMR.

Outcomes suggested a dose‑response–like relationship, with greater durability of weight‑loss maintenance observed as the extent of duodenal mucosal resurfacing increased.

Patients who underwent a more complete duodenal mucosal resurfacing, defined by successful treatment of a larger portion of the intended duodenal segment, regained a mean of approximately 7 lb and maintained more than 80% of their initial weight loss. In contrast, patients who received the sham procedure regained roughly twice as much weight.

Importantly, the metabolic benefit appeared sustained at 6 months, with investigators noting that the treatment effect increased rather than diminished over time. No major safety concerns were reported.

"Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need," said lead author Shelby Sullivan, MD of Dartmouth Geisel School of Medicine. "These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance.”

Source: DDW 2026. Simple ‘gut reset’ procedure may prevent weight rebound following GLP-1 discontinuation